Gliclada, 60 mg 30 pcs

Gliclazide is a sulfonylurea derivative, a hypoglycemic drug for oral administration, which differs from similar drugs by the presence of an N-containing heterocyclic ring with an endocyclic bond.

Indications

Type 2 diabetes mellitus with insufficient effectiveness of diet therapy, physical activity and weight loss.
Prevention of diabetes complications: reducing the risk of microvascular (nephropathy, retinopathy) and macrovascular complications (myocardial infarction, stroke) in patients with type 2 diabetes through intensive glycemic control.

Pharmacological effect

Gliclazide is a sulfonylurea derivative, a hypoglycemic drug for oral administration, which differs from similar drugs in the presence of an N-containing heterocyclic ring with an endocyclic bond.

Special instructions

Hypoglycemia
When taking sulfonylurea derivatives, including gliclazide, hypoglycemia may develop, in some cases in a severe and prolonged form, requiring hospitalization and intravenous administration of dextrose solution for several days (see section “Side effects”).

Active ingredient

Gliclazide

Composition

1 tablet contains:

Active ingredient:

Gliclazide 30.0 mg

Excipients:

hypromellose (4000 mPas*),

hypromellose (100 mPas*),

calcium carbonate,

lactose monohydrate,

colloidal silicon dioxide,

anhydrous,

magnesium stearate

* The figure represents the nominal viscosity values ​​for a 2% aqueous solution of hypromellose.

Pregnancy

Pregnancy

Contraindications

– Hypersensitivity to gliclazide, other sulfonylurea derivatives, sulfonamides or excipients included in the drug;
– diabetes mellitus type 1;
– diabetic ketoacidosis, diabetic precoma, diabetic coma;
– severe renal or liver failure (in these cases it is recommended to use insulin);
– taking miconazole (see section “Interaction with other drugs”);
– pregnancy and breastfeeding (see section “Use during pregnancy and breastfeeding”);
– age up to 18 years.
Due to the fact that the drug contains lactose, Glyclada® is not recommended for patients with congenital lactose intolerance, galactosemia, or glucose-galactose malabsorption.
It is not recommended to use in combination with phenylbutazone or danazol (see section “Interaction with other drugs”).

Side Effects

Given the experience with the use of gliclazide and other sulfonylurea derivatives, one should be aware of the possibility of developing the following side effects.

Interaction

Drugs that increase the risk of hypoglycemia (increasing the effect of gliclazide)

Overdose

In case of an overdose of sulfonylurea derivatives, hypoglycemia may develop.

Storage conditions

At a temperature not exceeding 25 °C, in the original packaging.

Keep out of the reach of children.

Shelf life

5 years.

Manufacturer

KRKA dd Novo Mesto, Slovenia